The importance of a robust DNA process
A robust DNA process that identifies those patients that have failed to have their INR test by the expected date increases patient safety and ensures that patients, particularly high risk/priority patients, don’t get missed.
The purpose of the DNA process is to identify those patients that have failed to have their INR test by the expected date, move the test date forward to an appropriate date in the future, reschedule the new appointment into the clinic diary and create the relevant non-attendance notice to send to the patient.
DAWN AC’s DNA workflow process uses an improved list view to segregate patients into two categories – the stable patients that can be bulk rescheduled, and the priority patients that should be dealt with individually, e.g. they are on bridging therapy, had a miss/boost dose instruction on their last visit, etc.
It also improves the workflow for rescheduling patients to make the process safer, more visible and more intuitive.
Where a patient has failed to have their INR test on a pre-determined number of occasions (set to 3 by default), their treatment plan will be set to non attending which means that the patient cannot be dosed.
The process is comprised of 4 main steps:
Step 1 – Identify Non Attenders for Rescheduling
Step 2 – Manual Rescheduling of Non Attenders (priority patients)
Step 3 – Automatic Rescheduling of Non Attenders (stable patients)
Step 4 – Dealing With Persistent Non Attenders
Read the DAWN DNA Process Guide on how to deal with patients that have not had an INR test by the expected date.
For more information, contact the DAWN support team at email@example.com